StemCell Therapy

SILVER SPRING, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

The Companys webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company's website at http://www.aziyo.com. The webcast will also be archived and available for replay.

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at http://www.lythampartners.com/spring2022invreg.

About Aziyo Biologics

Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit http://www.Aziyo.com.

Investors:Leigh Salvo Gilmartin Groupinvestors@aziyo.com

Read the original here:
Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference - GlobeNewswire

This entry was posted on April 2, 2022 at 1:48 am and is filed under Regenerative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |